Patent application EP16786732A (EP), filed 2016-04-27
Publication number: EP3290023A2
Title: RIVASTIGMINE-CONTAINING SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION
Abstract: [0001]    The present invention relates to a rivastigmine-containing sustained-release pharmaceutical composition and, more specifically, to a rivastigmine-containing sustained-release pharmaceutical composition, which is a sustained-release preparation containing a pH-dependent delayed release phase, wherein, by controlling the release of the pharmaceutical composition to be minimized in the stomach at the initial stage of administration, the pharmaceutical composition can lower the maximum blood concentration (Cmax) compared with existing products while arriving at an effective blood concentration, thereby reducing side effects, and thereafter, maintaining the effective blood concentration through the sustained-release of main ingredients. As a result, the pharmaceutical composition according to the present invention exhibits the same effect as in the existing twice-a-day dosing through only the once-a-day dosing, and can increase the treatment efficiency of patients through the improvement in the convenience of administration of patients.
IPC codes: A61K  31/    27            A I
A61K  47/    30            A I
A61K   9/    00            A I
A61K   9/    16            A I
A61K   9/    20            A I
A61K   9/    50            A I
A61P  25/    16            A I
A61P  25/    28            A I
Office action: search_report, dated 2018-03-07
Rejection reasons: novelty_epc_54
Prior art cited: ref_id: WO0113898
ref_type: patent
severity: novelty_destroying
Final disposition: pending (2018-03-07)